Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bristol Myers Squibb : Myers Gets FDA Priority Review for Opdivo/Yervoy for Non-Small Cell Lung Cancer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/15/2020 | 07:39am EST

By Colin Kellaher

Bristol-Myers Squibb Co. (BMY) said Wednesday the U.S. Food and Drug Administration accepted for priority review its supplemental biologics license application for Opdivo in combination with Yervoy for the treatment of a form of lung cancer.

The New York biopharmaceutical company said the filing covers the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations.

Non-small cell lung cancer is one of the most common types of lung cancer, accounting for up to 85% of diagnoses.

Bristol-Myers said the FDA set a target action date of May 15 for the application.

The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period to six months from the standard 10 months.

Write to Colin Kellaher at colin.kellaher@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB COMPA
01/27EXELIXIS : Announces Results for Combination of Cabozantinib and Nivolumab With ..
AQ
01/21Stocks to Watch: UBS, Delta, American Airlines, Pfizer
DJ
01/16BRISTOL-MYERS SQUIBB COMPANY : - U.S. Food and Drug Administration Accepts for P..
AQ
01/15BRISTOL MYERS SQUIBB : Myers Gets FDA Priority Review for Opdivo/Yervoy for Non-..
DJ
01/15BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Accepts for Priority Re..
BU
01/13BRISTOL MYERS SQUIBB : to Participate in the 38th Annual J.P. Morgan Healthcare ..
PU
01/13NEKTAR THERAPEUTICS : and Bristol-Myers Squibb Amend Strategic Collaboration Agr..
AQ
01/13Bristol-Myers Deal Starts to Pay Off as Treatments Advance -- WSJ
DJ
01/12BRISTOL'S MERGER WITH CELGENE IS ALR : Ceo
DJ
01/10BRISTOL-MYERS SQUIBB, MACY'S, GRUBHU : Stocks That Defined the Week
DJ
More news
Financials (USD)
Sales 2019 24 359 M
EBIT 2019 7 578 M
Net income 2019 6 460 M
Finance 2019 4 197 M
Yield 2019 2,60%
P/E ratio 2019 17,4x
P/E ratio 2020 11,1x
EV / Sales2019 5,96x
EV / Sales2020 4,21x
Capitalization 149 B
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 70,79  $
Last Close Price 63,70  $
Spread / Highest target 25,6%
Spread / Average Target 11,1%
Spread / Lowest Target -1,10%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Senior Vice President
Vicki L. Sato Lead Independent Director
Michael Grobstein Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-0.05%150 403
JOHNSON & JOHNSON1.68%390 359
ROCHE HOLDING AG3.03%284 454
PFIZER1.63%220 369
MERCK AND COMPANY-5.46%218 904
NOVARTIS-0.38%213 484